Experimental data from the 5xFAD AD animal model showed that 6‐TG administration leads to a marked reduction in the levels of pJAK2 and pSTAT1, suggesting that 6‐TG exerts its regulatory effect on BACE1 expression through the modulation of the STAT1 pathway. Here, STAT1 is linked to Alzheimer disease.